GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
Read More
Tag: Lennox-Gastaut
GW’s cannabinoid Epidiolex under EU, US review
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Read More
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
- eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
- Miranda Dini launches GOLD amid industry shifts
